CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- 4 Planned sale Director sold 57,600 shares at an average $15.19 ($875,100)
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Other acquisition Chief Financial Officer acquired 1,226 shares (other)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Financial Officer sold 1,296 shares at $9.29 ($12,033)
- 4 Open-market sale Chief Executive Officer sold 7,534 shares at $9.29 ($69,953)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Executive or director change
- 4 Open-market buy Chief Financial Officer bought 3,000 shares
- 4 Open-market buy Head of R&D, CMO bought 11,765 shares at $9.00 ($105,826)
- 4 Open-market buy Director bought 5,000 shares at $8.99 ($44,950)
- 4 Open-market buy Director bought 10,000 shares at $9.11 ($91,120)
- 3 Insider Initial Statement of Ownership
Page 4 of 33 · 660 filings